*Correspondence: Helton Estrela Ramos, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Thyroid Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Document any alternative medications that the patient has received or attempted, including any yes/no responses and dates
While both ShedRx and Remedy Meds offer pathways to access GLP-1s, Remedy Meds currently provides a more transparent, user-friendly option
Rather than severe calorie restriction, aim for gradual, sustainable weight loss without compromising milk supply
Mutations in the carboxyl-terminal domain of phospholipase C-1 delineate the dimer interface and a potential Gq interaction site
Quick Answer: GLP-1 medications show clinically meaningful average weight loss in large-scale peer-reviewed trials - approximately 14.9% for semaglutide (STEP 1) and up to 20.9% for tirzepatide (SURMOUNT-1) under trial conditions
